Wednesday January 24th, 2017
09.00 Chairperson’s Opening Remarks
ENHANCING PRECLINICAL STRATEGIES FOR DEVELOPING CANCER IMMUNOTHERAPIES THROUGH NEXT GENERATION PRECLINICAL RESEARCH
09.10 Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform
- James Keck Senior Director for the Clinical Lab & In Vivo Pharmacology Services, The Jackson Laboratory
- The addition of 3 human cytokines (GM-CSF, IL-3 & Kit Ligand) into the NSG mouse provide for a more robust myeloid compartment after humanization
- Showcase data on the myeloid engraftment kinetics and also show checkpoint inhibitor efficacy against several PDX tumors
09.40 Preclinical Modeling of Diverse Brain Tumor Subtypes via Single-Copy Somatic Transgenesis and CRISPR Genome Editing
- Joshua Breunig Assistant Professor, Cedars-Sinai Medical Center
- Overview of novel genetic methodologies for rapid, autochthonous tumor modeling
- Strategies for combining single-copy somatic transgenesis with CRISPR genome editing to generate patient-derived mutation signatures in mouse models to accurately model clinical tumor subtypes in a “personalized” manner
- Examples of preclinical studies investigating strategies to impede tumor growth and development by immunotherapy, metabolic targeting, and therapeutic mimicry
10.10 Pre-clinical Modeling of Immune Responses to Cancer: From Bench-Side to Clinical Outcomes
- Mithun Khattar Immuno-oncology lead, Takeda
- Fundamental differences in immune composition, tumor microenvironments and disease progression between mice and humans.
- Preclinical models in immune-oncology: what translates and what doesn’t.
- How to leverage the data from pre-clinical studies and minimize translational failures.
10.40 Developing checkpoint target humanized models for preclinical efficacy assessment
- Toni Jun Director of Scientific Engagement , Crown Bioscience
- Lack of animal models for efficacy evaluation of human therapeutic antibodies for cancer Immunotherapies
- HuGEMM models, expressing chimeric checkpoint targets with human extracellular domains, allow the evaluation of specific human biological therapies in vivo
11.10 Speed Networking
11.40 Morning Refreshments
12.10 Utilising 3D Tumor Models Built With Scalable Bioprinting Technology to Improve Cancer Drug Development
- Kolin Hribar CEO and Founder, Cypre, Inc
- A new type of 3D bioprinting technology for screening
- Patient-derived tumor testing for precision medicine
- Assaying immuno-oncology in 3D
ENHANCING THE POWER OF PREDICTIVE PRECLINICAL RESEARCH TO FORWARD THE CLINICAL SUCCESS OF YOUR ADOPTIVE CELL THERAPIES
12.40 T Cell Co-Stimulation: A Potent Pathway for Improved Adoptive Cell Therapy
- Dr. Abhishek Srivastava Assistant Professor, University of Pittsburgh
- Tumor Infiltrating Lymphocytes (TIL) therapy) and its impact on the melanoma patients
- Ex-vivo reprogramming of T cells for improved therapy
- Learn how to test these reprogrammed TILs in In vivo mice model
13.10 Understanding T cell Exhaustion in Common Syngeneic Tumor Models
- Rafael Cubas Barcelli Scientist, Genentech
- Co-expression of the inhibitory receptors PD1/LAG3/TIM3 enriches for highly activated CD8 T cells in established syngeneic tumor models
- Reduced functionality of TILs is observed in the PD1- population rather than the PD1+ CD8 T cell subset.
- Caution must be exercised when using inhibitory receptor expression alone to define T cell functionality in commonly used syngeneic tumor models
MINIMIZING THE TRANSLATIONAL GAP FROM PRECLINICAL TO CLINICAL THROUGH NEXT GENERATION IN VIVO MODELS
14.40 Optimizing In Vivo Models for the Development of Autologous T cell Therapies
- Shon Green Preclinical Development, Eureka Therapeutics
- What models are being utilized to evaluate efficacy of engineered T-cell therapies?
- How do we overcome the limitations of immune-compromised mice?
- Characterizing your T cells in vivo to extract correlates with efficacy
15.10 Circulating Tumor Cell (CTC) Analysis in Preclinical Models of Cancer Metastasis
- Lori Lowes Post-Doctoral Research Fellow, London Health Sciences Centre
- In the development of novel cancer therapies, there is a critical need for in vivo preclinical models that will allow assessment of metastasis.
- A number of quantitative tools have been previously developed to study in vivo metastasis, the detection and quantification of rare metastatic events has remained challenging.
- This presentation will discuss the use of circulating tumor cell (CTC) analysis as an effective means of tracking and characterizing metastatic disease progression in preclinical mouse models of breast and prostate cancer.
- In particular, the use of clinically-relevant CTC technologies such as the Parsortix platform (ANGLE plc) can serve to enhance the translation of cancer biology and new cancer therapies from animal to patient.
15.25 Advanced PDX Tumor Biology Platforms for Drug Advancement
- Neal Goodwin Vice President, Corporate Research & Development, Champions Oncology
- Harnessing large collections of PDX models for more resolute efficacy predictions and the discovery of new therapeutic targets, resistance mechanisms, and biomarker signatures of response
- How robust systems of myeloid engraftment, including hematopoietic stem cells for immune-oncology modeling and AML engraftment for high throughput multipatient in vivo screens, have now provided expanded PDX screening with a wider scope of therapeutic agents
- Advancement of coupled-PDX trials, where clinical trials are combined with companion PDX studies to help guide follow-on trial design
15.55 Afternoon Refreshments
16.25 Humanized mouse models for drug discovery research
- Barbara Joyce-Shaikh Associate Principal Scientist, Merck
- Development of humanized in vivo models to develop IO therapeutics
- Explore the advantages and limitations of humanized vs syngeneic systems
- Leveraging humanized systems for deciphering mechanism of action and clinical translation